Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis

By sjmartinez • April 27, 2023

Spiera R, Kuwana M, Khanna D, Hummers L, Frech TM, Stevens W, Matucci-Cerinic M, Kafaja S, Distler O, Jun JB, Levy Y, Leszcyzński P, Gordon J, Steen V, Lee EB, Jankowski T, Litinsky I, Chung L, Hsu V, Mayes M, Sandorfi N, Simms RW, Finzel S, de Vries-Bouwstra J, Constantine S, Dgetluck N, Dinh Q, Bloom BJ, Furst DE, White B, Denton CP; RESOLVE-1 Study Group. Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis. Arthritis Rheumatol. 2023 Apr 26. doi: 10.1002/art.42510. Epub ahead of print. PMID: 37098795.

Tags: Publications, Rheumatology

Diet, nutrition, and hormone therapy for prostate cancer: a systematic review with implications for future interventions

Pahulu I, Calumpit M, Tominez P, Shih JJ, Ebrahimi S, Deville NV, Samoa R, Moin T, Sedrak MS, Valle LF, Steinberg M, Kishan AU, Ganz[...]

The malate-aspartate shuttle supports thermogenic lipid mobilization in brown adipocytes

Veliova M, Ferreira CM, Montales KP, Villalobos F, Brownstein AJ, Acín-Pérez R, Ferreira GS, Jones AE, Stiles L, Divakaruni AS, Liesa M, Shirihai OS, Oliveira[...]

Regional Comparisons of the Prevalence and Socioeconomics of Hepatitis Delta Virus in Two Southern California Counties

Pak K, Leng M, Nguyen J, Moussa K, Gish R, Han SH, Pockros P. Regional Comparisons of the Prevalence and Socioeconomics of Hepatitis Delta Virus[...]